Novel agents and future directions for refractory breast cancer

Seminars in Oncology

Volumn 38, Issue SUPPL. 2, 2011, Pages

  Burstein, Harold J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; BRCA2 PROTEIN; CAPECITABINE; CARBOPLATIN; DASATINIB; EVEROLIMUS; EXEMESTANE; GEMCITABINE; INIPARIB; IXABEPILONE; LETROZOLE; NAVELBINE; OLAPARIB; PACLITAXEL; POLY(ADENOSINE DIPHOSPHATE RIBOSE); TEMOZOLOMIDE; TEMSIROLIMUS; TRASTUZUMAB; VELIPARIB;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER RESISTANCE; CONFERENCE PAPER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FLUID RETENTION; GASTROINTESTINAL DISEASE; GASTROINTESTINAL SYMPTOM; GENE MUTATION; HUMAN; MOOD DISORDER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SOMNOLENCE; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA; DRUG RESISTANCE, NEOPLASM; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; FEMALE; HUMANS; MEDICAL ONCOLOGY; MODELS, BIOLOGICAL; PHOSPHATIDYLINOSITOL 3-KINASES; POLY(ADP-RIBOSE) POLYMERASES; SRC-FAMILY KINASES;

EID: 79956195555     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2011.04.002     Document Type: Conference Paper

References (30)

1. L. Rosen, H.L. Ashurst, and L. Chap Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review Oncologist 15 2010 216 235
2. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
3. J.-C. Am, C. Spenlehauer, and G. de Murcia The PARP superfamily BioEssays 26 2004 882 893 (Pubitemid 39128102)
4. T. Helleday, E. Petermann, C. Lundin, B. Hodgson, and R.A. Sharma DNA repair pathways as targets for cancer therapy Nature Rev Cancer 8 2008 193 204 (Pubitemid 351301852)
5. H. Farmer, N. McCabe, and C.J. Lord Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921 (Pubitemid 40559006)
6. O'Shaughnessy, Osborne C, Pippen J, et al. Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial. Paper presented at the 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29-June 2; Orlando, FL.
7. NCT00938652 A phase 3, multi-center study of gemcitabine/carboplatin, with or without BSI-201, in patients with ER-, PR-, and Her2-negative metastatic breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
8. Tutt A, Robson M, Garber JE, et al. Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Paper presented at the 45th Annual Meeting of the American Society of Clinical Oncology; 2009 May 29-June 2; Orlando, FL.
9. S.J. Isakoff, B. Overmoyer, and N.M. Tung A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer [abstract 1019] J Clin Oncol 28 15S, Part I 2009 118s
10. J. Zhou, J. Wulfkuhle, and H. Zhang Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance PNAS 104 2007 16158 16163 (Pubitemid 350099378)
11. M. Beeram, Q.-T.N. Tan, R.R. Tekmal, D. Russell, A. Middleton, and L.A. deGraffenried Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann Oncol 18 2007 1323 1328 (Pubitemid 47305004)
12. J. Baselga, V. Semiglazov, and P. van Dam Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer J Clin Oncol 27 2009 2630 2637
13. M. Boulay, J. Rudloff, and Y. Jingjing Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 11 2005 5319 5328 (Pubitemid 41003721)
14. NCT00876395 Everolimus in combination with trastuzumab and paclitaxel in the treatment of her2 positive locally advanced or metastatic breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
15. NCT01007942 Daily everolimus in combination with trastuzumab and vinorelbine in HER2/neu positive women with locally advanced or metastatic breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
16. NCT00567554 A phase III trials program exploring the integration of bevacizumab, everolimus (RAD001), and lapatinib into current neoadjuvant chemotherapy regimes for primary breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
17. NCT00863655 Everolimus in combination with exemestane in the treatment of postmenopausal women with estrogen receptor positive locally advanced or metastatic breast cancer who are refractory to letrozole or anastrozole http://www.clinicaltrials.gov Accessed January 13, 2011
18. L.W.C. Chow, Y. Sun, and J. Jassem Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer [abstract 6091] Breast Cancer Res Treat 100 Suppl 1 2006
19. B.S. Verbeek, T.M. Vroom, and S.S. Adriaansen-Slot Src protein expression is increased in human breast cancer An immunohistochemical and biochemical analysis J Pathol 180 1996 383 388 (Pubitemid 27014075)
20. E. Mayer, and E. Krop Advances in targeting Src in the treatment of breast cancer and other solid malignancies Clin Cancer Res 16 2010 3526 3532
21. E. Mayer, J. Baurain, and J. Sparano Dasatinib in advanced HER2/neu amplified and ER/PR-positive breast cancer: phase II study CA180088 [abstract 1011] J Clin Oncol 27 15S, Part I 2009 43s
22. C. Pichot, S.M. Hartig, and L. Xia Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells Br J Cancer 101 2009 38 47
23. Sprycel [package insert] 2009 Bristol-Myers Squibb Princeton, NJ
24. R. Finn, J. Dering, and C. Ginther Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro Breast Cancer Res Treat 105 2007 319 326 (Pubitemid 47596452)
25. NCT00820170 Dasatinib in combination with weekly paclitaxel for patients with metastatic breast carcinoma http://www.clinicaltrials.gov Accessed February 23, 2011
26. NCT00780676 Personalized treatment selection for dasatinib in metastatic breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
27. NCT00767520 Safety and efficacy of exemestane plus dasatinib versus placebo for advance ER+ breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
28. NCT00924352 Trial of dasatinib plus ixabepilone in 2nd or 3rd line metastatic breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
29. NCT00452673 Phase I study of dasatinib (BMS-354825) and capecitabine for women with advanced breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011
30. NCT00546104 Phase II dasatinib study in advanced breast cancer http://www.clinicaltrials.gov Accessed January 13, 2011